These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 19855169)

  • 1. Targeting biodefense markets.
    Olinger GG
    Hum Vaccin; 2009 Oct; 5(10):660-5. PubMed ID: 19855169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Making vaccines "on demand": a potential solution for emerging pathogens and biodefense?
    De Groot AS; Einck L; Moise L; Chambers M; Ballantyne J; Malone RW; Ardito M; Martin W
    Hum Vaccin Immunother; 2013 Sep; 9(9):1877-84. PubMed ID: 23877094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phacilitate vaccine forum Barcelona 2009.
    Silman NJ; Rivera LM; Wheat J
    Expert Rev Vaccines; 2009 Oct; 8(10):1329-31. PubMed ID: 19803754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Taking aim at novel vaccines market.
    Awasthi S
    Hum Vaccin; 2009 Oct; 5(10):654-7. PubMed ID: 19855156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioterrorism and the Role of the Clinical Microbiology Laboratory.
    Wagar E
    Clin Microbiol Rev; 2016 Jan; 29(1):175-89. PubMed ID: 26656673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disaster Preparedness: Biological Threats and Treatment Options.
    Narayanan N; Lacy CR; Cruz JE; Nahass M; Karp J; Barone JA; Hermes-DeSantis ER
    Pharmacotherapy; 2018 Feb; 38(2):217-234. PubMed ID: 29236288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Biodefense: a new challenge for microbiology and public health].
    ; Buitrago Serna MJ; Casas Flecha I; Eiros-Bouza JM; Escudero Nieto R; Giovanni Fedele C; Jado García I; Pozo Sánchez F; Rubio Muñoz JM; Sánchez-Seco Fariñas MP; Valdezate Ramos S; Verdejo Ortes J
    Enferm Infecc Microbiol Clin; 2007 Mar; 25(3):190-8. PubMed ID: 17335699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agility in adversity: Vaccines on Demand.
    De Groot AS; Moise L; Olive D; Einck L; Martin W
    Expert Rev Vaccines; 2016 Sep; 15(9):1087-91. PubMed ID: 27389971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Federal agency biodefense funding, FY2012-FY2013.
    Franco C; Sell TK
    Biosecur Bioterror; 2012 Jun; 10(2):162-81. PubMed ID: 22691277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biodefense. Army halts work at lab after finding untracked material.
    Bhattacharjee Y
    Science; 2009 Feb; 323(5916):861. PubMed ID: 19213883
    [No Abstract]   [Full Text] [Related]  

  • 11. Bioterrorism: myth or reality?
    Greub G; Grobusch MP
    Clin Microbiol Infect; 2014 Jun; 20(6):485-7. PubMed ID: 24920295
    [No Abstract]   [Full Text] [Related]  

  • 12. Biodefense: trends and challenges in combating biological warfare agents.
    Tegos GP
    Virulence; 2013 Nov; 4(8):740-4. PubMed ID: 24241242
    [No Abstract]   [Full Text] [Related]  

  • 13. Incentives for biodefense countermeasure development.
    Matheny J; Mair M; Mulcahy A; Smith BT
    Biosecur Bioterror; 2007 Sep; 5(3):228-38. PubMed ID: 17903091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Confronting the threat of bioterrorism: realities, challenges, and defensive strategies.
    Green MS; LeDuc J; Cohen D; Franz DR
    Lancet Infect Dis; 2019 Jan; 19(1):e2-e13. PubMed ID: 30340981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. U.S. medical countermeasure development since 2001: a long way yet to go.
    Russell PK; Gronvall GK
    Biosecur Bioterror; 2012 Mar; 10(1):66-76. PubMed ID: 22455680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Billions for biodefense: federal agency biodefense funding, FY2009-FY2010.
    Franco C
    Biosecur Bioterror; 2009 Sep; 7(3):291-309. PubMed ID: 19772453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stem cells serve as new platform for biodefense preparedness.
    May M
    Nat Med; 2010 Aug; 16(8):835. PubMed ID: 20689533
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative pathogenesis and systems biology for biodefense virus vaccine development.
    Bowick GC; Barrett AD
    J Biomed Biotechnol; 2010; 2010():236528. PubMed ID: 20617142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Legal preparedness for bioterrorism.
    Matthews GW; Benjamin G; Mills SP; Parmet W; Misrahi JJ
    J Law Med Ethics; 2002; 30(3 Suppl):52-6. PubMed ID: 12508503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Federal funding for health security in FY2015.
    Boddie C; Sell TK; Watson M
    Biosecur Bioterror; 2014; 12(4):163-77. PubMed ID: 24988432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.